Aditum Bio Management Company, LLC

About

--> Home | Aditum Bio | Translating Science, Benefiting Patients top of page TRANSLATING SCIENCE Benefiting patients We’re taking biotech venture capital where it needs to go bottom of page --> About | Aditum Bio | Biotechnology Assets to Benefit Patients top of page About Us: Overview TRANSLATING SCIENCE TO IMPR OVE PATIENTS LIVES Aditum Bio is a new model of biotech ve n ture capital, uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. About NEW MODEL OF VENTURE CAPITAL AGILE, INVENTIVE, RESPONSIVE Aditum Bio brings together unmatched scientific and domain expertise with agile operational capabilities. Our unique investment and operating model enables rapid company formation, planning, and execution to advance novel drug candidates into the clinic and speed their delivery to the patients in need. ​ ​ Overview Values Approach PROVEN INDUSTRY LEADERSHIP AND SCIENTIFIC EXPERTISE Launched by former Novartis CEO, Joe Jimenez, and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the experience of our founding executive team provides Aditum Bio with a unique lens for identifying and selecting innovative drug candidates with unrecognized potential. Meet Our Team BETTER OUTCOMES FOR PATIENTS. FASTER RETURNS FOR INVESTORS. By singularly focusing on the translation phase of drug development, Aditum Bio efficiently identifies and develops potentially first- and best-in-class therapies for a broad array of

Key Contact

Geographic Focus